Zhirong Qian is one of Sun Yat-sen University's “Hundred Talents Program” introduced talents and he currently works at the Research Center of the Seventh Affiliated Hospital of Sun Yat-sen University, qualified and competent for both Ph.D. and postdoctoral supervisor. He has served successively as an assistant professor of the Department of Human Pathology at the National University of Tokushima in Japan, and a postdoctoral researcher at Dana-Farber Cancer Institute of Harvard Medical School. Up to now, he has supervised dozens of Ph.D. and postdoctoral fellows.
Zhirong Qian is a member of the International Molecular Pathology Epidemiology Committee, a director of the Japanese Endocrine Pathology Society, an editorial board of the International Journal of Clinical and Experimental Pathology, deputy editor of Chronic Diseases and Translational Medicine, and a consultant specialised in molecular oncology and immunotherapy at the Chinese Research Hospital committee. In recent years, he has chaired and participated in many NIH/NCI and Harvard University research funds, with a total amount of over 100 million dollars. He also provided quality papers to several internationally renowned academic journals of oncology where a total of 120 SCI papers are published with total impact factors of more than 1000. Among these papers, more than 20 pieces of IF≥20 articles are published by including NEJM, Nature, Nature Medicine, Nature Genetics, JAMA, JCO, Gastroenterology, Gut, JAMA Oncology and Cancer Discover, being referenced more than 5500 times as well. Explicitly, he as the first author, the correspondence author, the co-first author, the co-senior author, and the senior author has 48 SCI papers published, including eight papers with IF≥ 10 and two papers with IF≥ 20. For these reasons, he has been awarded with many academic honours at both the national and worldwide level.
Researcher Qian's expertise lies in the application and analysis of large epidemiological databases, the collection, construction and analysis of large clinical materials, second-generation gene sequencing and analysis, molecular pathology, tumour molecular biology, anticancer drug target discovery and drug development, and surgical pathology.
Publication:
1. Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM. Alterations in Main Driver Genes Predict Patient Outcomes in Resected Pancreatic Ductal Adenocarcinoma; JAMA Onco 2017 PMID 29098284
2. Hamada T, Cao Y, Qian ZR*, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, Silva Ad, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (PD-L1) Expression Status. J Clin Oncol 2017 PMID 28406723
3. Qian ZR*, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic significance of MTOR pathway components expression in neuroendocrine tumors. J Clin Oncol 2013;31:3418-25. PMCID: PMC3770868
4. Cao Y, Nishihara R, Qian ZR*, Song M, Mima K, Inamura K, Nowak JA, Drew DA, Lochhead P, Nosho K, Morikawa T, Zhang X, Wu K, Wang M, Garrett WS, Giovannucci EL, Fuchs CS, Chan AT, Ogino S. Regular Aspirin Use Associates with Lower Risk of Colorectal Cancers With Low Numbers of Tumor-infiltrating Lymphocytes. Gastroenterology. 2016 Jul 27. PMID: 27475305
5. Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak J, Nosho K,Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR*, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2016 May 5. [Epub ahead of print]. PMCID pending, PMC journal – in process,
6. Mima K, Nishihara R, Qian ZR*, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2015;1:653-61. PMCID: PMC4537376
7. Song M, Nishihara R, Wu K, Qian ZR*, Kim SA, Sukawa Y, Mima K, Inamura K, Masuda A, Yang J, Fuchs CS, Giovannucci EL, Ogino S, Chan AT. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst 2015;107(4). PMCID: PMC4402363
8. Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, da Silva A, Cao Y, Song M, Nowak J, Gu M, Li W, Morikawa T, Zhang X, Wu K, Baba H, Giovannucci EL, Meyerhardt JA, Chan AT, Fuchs CS, Qian ZR*, Ogino S. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016 Mar 8. [Epub ahead of print]. PMCID pending, PMC journal – in process,
9. Mima K, Nishihara R, Nowak JA, Kim SA, Song M, Inamura K, Sukawa Y, Masuda A, Yang J, Dou R, Nosho K, Baba H, Giovannucci EL, Bowden M, Loda M, Giannakis M, Bass AJ, Dranoff G, Freeman GJ, Chan AT, Fuchs CS, Qian ZR*, Ogino S. MicroRNA MIR21 and T cells in colorectal cancer. Cancer Immunol Res 2016;4:33-40. PMCID: PMC4703429
10. Dou R, Nishihara R, Cao Y, Hamada T, Mima K, Masuda A, Masugi Y, Shi Y, Gu M, Li W, da Silva A, Nosho K, Zhang X, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Qian ZR*, Ogino S. MicroRNA let-7, T cells, and patient survival in colorectal cancer. Cancer Immunol Res 2016 Oct. Published Online
11. Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC, Fuchs CS, Wu K, Chan AT, Zhang X, Ogino S, Qian ZR. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 2016;114:199-206. PMCID:PMC4815802
12. Hanyuda A, Ogino S, Qian ZR, Nishihara R, Song M, Mima K, Inamura K, Masugi Y, Wu K, Meyerhardt JA, Chan AT, Fuchs CS, Giovannucci EL, Cao Y. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer. 2016 Aug 15;139(4):854-68. PMID: 27037951
Email Address: qianzhir@mail.sysu.edu.cn